Effects of elexacaftor-tezacaftor-ivacaftor on daily treatment burden and airflow obstruction in adults with cystic fibrosis.

Pulmonary pharmacology & therapeutics（2023）

引用 0|浏览6

暂无评分

摘要

ETI therapy can reduce the daily treatment burden in real-life at 6 months of treatment, increase a large number of lung function parameters and improve airflow obstruction.

查看译文

关键词

List: airflow obstruction,Cystic fibrosis,Elexacaftor-tezacaftor-ivacaftor,Distal airways,Daily treatment burden

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要